A Study to Assess Drug-drug Interaction of ZX008 in Healthy Male and Female Study Participants
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-11-07
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- UCB BIOSCIENCES, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT06679413
- Locations
- 🇺🇸
Up0132 1001, Baltimore, Maryland, United States
Doxecitine and Doxribtimine-Expanded Access
- Conditions
- First Posted Date
- 2024-09-11
- Last Posted Date
- 2024-09-11
- Lead Sponsor
- UCB BIOSCIENCES, Inc.
- Registration Number
- NCT06590493
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet Syndrome
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- UCB BIOSCIENCES, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT06118255
- Locations
- 🇪🇸
Ep0213 601, Barcelona, Spain
🇺🇸Ep0213 106, Orange, California, United States
🇺🇸Ep0213 102, Winston-Salem, North Carolina, United States
An Open-Label Study of Continuation Treatment With Combination Pyrimidine Nucleosides in Patients With TK2 Deficiency
Phase 2
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2019-02-19
- Last Posted Date
- 2023-11-21
- Lead Sponsor
- UCB BIOSCIENCES, Inc.
- Target Recruit Count
- 47
- Registration Number
- NCT03845712
- Locations
- 🇮🇱
Tk0102 4037, Nehariya, Israel
🇮🇱Tk0102 4038, Haifa, Israel
🇮🇱Tk0102 4039, Holon, Israel
Open-label, Bioequivalence Study of Certolizumab Pegol 200 mg Solution Injected Either by a Prefilled Syringe (Reference) or by an E-Device (Test) in Healthy Subjects
- First Posted Date
- 2016-06-20
- Last Posted Date
- 2016-11-17
- Lead Sponsor
- UCB BIOSCIENCES, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT02806219
- Locations
- 🇺🇸
Ra0132 001, Baltimore, Maryland, United States
UCB Cimzia Pregnancy Follow-up Study
- First Posted Date
- 2016-05-17
- Last Posted Date
- 2021-04-22
- Lead Sponsor
- UCB BIOSCIENCES, Inc.
- Target Recruit Count
- 1
- Registration Number
- NCT02775656
- Locations
- 🇺🇸
Up0019 001, Wilmington, North Carolina, United States
Study to Investigate Safety and Tolerability of Intravenous Lacosamide in Children.
- First Posted Date
- 2016-03-17
- Last Posted Date
- 2023-02-23
- Lead Sponsor
- UCB BIOSCIENCES, Inc.
- Target Recruit Count
- 103
- Registration Number
- NCT02710890
- Locations
- 🇺🇸
Ep0060 005, Dallas, Texas, United States
🇮🇹Ep0060 503, Messina, Italy
🇺🇦Ep0060 221, Kiev, Ukraine
Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects ≥1 Month to <4 Years With Partial-onset Seizures
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-06-23
- Last Posted Date
- 2021-07-01
- Lead Sponsor
- UCB BIOSCIENCES, Inc.
- Target Recruit Count
- 255
- Registration Number
- NCT02477839
- Locations
- 🇨🇳
Sp0967 537, Shenzhen, China
🇬🇷Sp0967 542, Athens, Greece
🇷🇺Sp0967 456, Nizhny Novgorod, Russian Federation
Safety and Efficacy of Lacosamide as Additional Therapy in Patients Suffering From Epileptic Tonic-Clonic Seizures
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-04-03
- Last Posted Date
- 2023-12-14
- Lead Sponsor
- UCB BIOSCIENCES, Inc.
- Target Recruit Count
- 239
- Registration Number
- NCT02408549
- Locations
- 🇺🇸
EP0012 8, Santa Monica, California, United States
🇵🇱Ep0012 651, Katowice, Poland
🇵🇱Ep0012 650, Warszawa, Poland
A Study to Assess the Safety and Efficacy of Lacosamide Versus Placebo (a Pill Without Active Medication) in Patients With Idiopathic Generalised Epilepsy Who Are Already Taking Anti-epileptic Medications
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-04-03
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- UCB BIOSCIENCES, Inc.
- Target Recruit Count
- 242
- Registration Number
- NCT02408523
- Locations
- 🇺🇸
Sp0982 018, Irvine, California, United States
🇺🇸Sp0982 034, Houston, Texas, United States
🇧🇬Sp0982 501, Sofia, Bulgaria
© Copyright 2024. All Rights Reserved by MedPath